Dyne Therapeutics (NASDAQ:DYN) Director Jason Rhodes Sells 195,427 Shares

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 195,427 shares of the business’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $21.14, for a total transaction of $4,131,326.78. Following the sale, the director directly owned 975,931 shares of the company’s stock, valued at approximately $20,631,181.34. The trade was a 16.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Price Performance

Shares of NASDAQ DYN opened at $22.21 on Wednesday. Dyne Therapeutics, Inc. has a fifty-two week low of $8.06 and a fifty-two week high of $25.00. The stock has a market cap of $3.67 billion, a price-to-earnings ratio of -6.90 and a beta of 1.09. The company has a debt-to-equity ratio of 0.17, a quick ratio of 19.92 and a current ratio of 19.92. The firm’s 50-day simple moving average is $18.52 and its 200 day simple moving average is $18.12.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.04. During the same period last year, the company posted ($1.05) EPS. As a group, research analysts anticipate that Dyne Therapeutics, Inc. will post -3 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

DYN has been the subject of several recent research reports. Wall Street Zen upgraded Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 20th. Evercore set a $33.00 price objective on shares of Dyne Therapeutics in a report on Friday, May 15th. HC Wainwright cut their price target on shares of Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, March 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Monday, April 20th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Dyne Therapeutics in a report on Monday, March 9th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $34.17.

Hedge Funds Weigh In On Dyne Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. grew its stake in Dyne Therapeutics by 9.0% during the third quarter. JPMorgan Chase & Co. now owns 3,365,245 shares of the company’s stock valued at $42,570,000 after acquiring an additional 278,466 shares in the last quarter. Aberdeen Group plc lifted its stake in Dyne Therapeutics by 99.0% in the 4th quarter. Aberdeen Group plc now owns 1,108,145 shares of the company’s stock worth $21,675,000 after purchasing an additional 551,412 shares in the last quarter. Vanguard Group Inc. lifted its stake in Dyne Therapeutics by 27.6% in the 3rd quarter. Vanguard Group Inc. now owns 9,760,414 shares of the company’s stock worth $123,469,000 after purchasing an additional 2,109,257 shares in the last quarter. SG Americas Securities LLC bought a new position in Dyne Therapeutics in the 4th quarter valued at $5,191,000. Finally, Fisher Asset Management LLC bought a new position in Dyne Therapeutics in the 4th quarter valued at $4,891,000. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.